SV Health Investors LLC

Search
⚲

SV Health Investors LLC ✚
CRD #	160933
SEC #	801-110943
CIK #	0001587143
AUM	1,080.3 M (2026-03-31)
Employees	26 (62% Investors, 0% Brokers)
Fees
Minimum
Phone	617-367-8100
Address	28 State Street Boston, MA 02109
Source	[IAPD] [EDGAR] [Website] [LinkedIn]

Total AUM ($B) Copy

Sector	Form 13F Holdings	Value ($M)
	Bicycle Therapeutics PLC	21.1
	Bioventus Inc	10.4
	Arsanis Inc	0.5

Holdings by Sector ($M)

Type	Form D Funds	Date	Sold	AUM
Other	SV7 Plus Growth Fund LP	[2025-03-31]		35.6 M
	Offered $60,000,000 · Filed 2024-11-05 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $60,000,000 · Duration One year or less · Revenue Not Applicable
VC	SV TREX CoInvestment LP	2025-03-31		8.0 M
Other	SV7 Growth Fund Strategic Partners LP	[2023-03-30]		15.5 M
	Filed 2022-04-28 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable
VC	SV Life Sciences Fund IV CF LP	2022-03-31		410.4 M
VC	Medtech Convergence Fund LP	[2019-03-29]		80.2 M
	Offered $94,000,000 · Filed 2019-03-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $94,000,000 · Duration One year or less · Revenue Not Applicable
Other	SV7 Growth Fund LP	[2019-03-29]	91.3 M	155.3 M
	Offered $250,000,000 · Filed 2020-11-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining $158,690,177 · Duration More than one year · Revenue Not Applicable
VC	DDF Parallel LLP	[2017-06-30]	26.0 M	19.3 M
	Offered $302,381,000 · Filed 2017-10-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $276,413,669 · Duration More than one year · Revenue Not Applicable
VC	SV Life Sciences Fund VI Strategic Partners LP	[2017-06-30]	13.1 M	8.7 M
	Offered $13,130,000 · Filed 2017-04-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Not Applicable
VC	SV Life Sciences Fund VI Strategic Partners LP	[2017-06-30]	13.1 M	13.3 M
	Offered $13,130,000 · Filed 2017-04-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Not Applicable
VC	Dementia Discovery LP	[2016-03-30]	26.0 M	169.6 M
	Offered $302,381,000 · Filed 2017-10-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $276,413,669 · Duration More than one year · Revenue Not Applicable
VC	SV Life Sciences Fund VI LP	[2016-03-30]	273.5 M	201.5 M
	Offered $400,000,000 · Filed 2016-05-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $126,500,000 · Duration One year or less · Revenue Not Applicable
VC	International Life Sciences Fund III Co-Investment LP	2012-03-30		0.5 M
VC	International Life Sciences Fund III LP1 LP	2012-03-30		15.6 M
VC	International Life Sciences Fund III LP2 LP	2012-03-30		8.0 M
VC	International Life Sciences Fund III Strategic Partners LP	2012-03-30		0.3 M
VC	Schroder Ventures International Life Sciences Fund Co-Investment Scheme	2012-03-30
VC	Schroder Ventures International Life Sciences Fund II Co-Investment Scheme	2012-03-30
VC	Schroder Ventures International Life Sciences Fund II LP1	2012-03-30
VC	Schroder Ventures International Life Sciences Fund II LP2	2012-03-30
VC	Schroder Ventures International Life Sciences Fund II LP3	2012-03-30
VC	Schroder Ventures International Life Sciences Fund II Strategic Partners LP	2012-03-30
VC	Schroder Ventures International Life Sciences Fund LP1	2012-03-30
VC	Schroder Ventures International Life Sciences Fund LP2	2012-03-30
VC	Schroder Ventures International Life Sciences Fund Trust	2012-03-30
VC	SV Life Sciences Fund IV LP	2012-03-30		5.2 M
VC	SV Life Sciences Fund IV Strategic Partners LP	[2012-03-30]		0.1 M
VC	SV Life Sciences Fund V LP	[2012-03-30]	407.2 M	138.5 M
	Offered $500,000,000 · Filed 2010-03-10 (D/A) · Exemption 506, 3(c), 3(c)(7) · Remaining $92,773,195 · Duration More than one year · Revenue Not Applicable
VC	SV Life Sciences Fund V Strategic Partners LP	[2012-03-30]	10.6 M	4.1 M
	Offered $10,575,000 · Filed 2010-04-07 (D) · Exemption 506, 3(c), 3(c)(1) · Minimum $25,000 · Duration One year or less · Revenue Not Applicable

AUM Breakdown	Accounts	AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	21	1.1
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	15	1.1
By Discretionary
Discretionary	15	1.1
Non-Discretionary	0	0.0
Total	15	1.1
By Non-United States Persons
Non-United States Persons		0.0
United States Persons		1.1
Total	15	1.1

Form D Directors	Role	# Filings	# Firms
Michael Ross	Executive Officer	88	5
James Garvey	Executive Officer	42	4
Michael Balmuth	Executive Officer	19	3
Kate Bingham	Executive Officer	8	3
Paul Laviolette	Executive Officer	59	2
David Milne	Executive Officer	40	2
Thomas Flynn	Executive Officer	34	2
Aaron Sandoski	Executive Officer	21	2
Eugene Hill	Executive Officer	20	2
Lutz Giebel	Executive Officer	19	2
View All

EDGAR Form	CIK	2011 - 2026
13F-HR	[0001587143]

Firm Profile (Form ADV)
Serves	Institutional

Comparable Firms	State	AUM
NexPoint Real Estate Advisors X LP ✚	TX	1,098.2 M
Asset Consulting Group LLC ✚	MO	1,096.1 M
CS Capital Management Inc ✚	CA	1,090.3 M
Riot Ventures Management LLC ✚	CA	1,086.1 M
CIM Capital IC Management LLC ✚	CA	1,080.5 M
Power Sustainable Manager US Inc ✚	FL	1,072.6 M
Counterpointe Investment Management LLC ✚	CT	1,067.7 M
Twin Oak ETF Company ✚	MA	1,057.8 M
Nordea Investment Management North America Inc ✚	NY	1,054.5 M
Virtus Alternative Investment Advisers LLC ✚	CT	1,053.0 M

SV Health Investors LLC

Assets, Funds, Holdings